<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01321749</url>
  </required_header>
  <id_info>
    <org_study_id>RIPC2011</org_study_id>
    <nct_id>NCT01321749</nct_id>
  </id_info>
  <brief_title>The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, single-center trial, designed to observe the effect
      of remote limb ischemic preconditioning on ischemic cerebral vascular disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure and Heart Rates;</measure>
    <time_frame>at the time points of baseline and 1, 15 and 30 days after BLIPC treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Biomarkers of Coagulation and Fibrinolysis</measure>
    <time_frame>the time points of baseline and 1, 15 and 30 days after BLIPC treatment</time_frame>
    <description>blood samples were collected one hour after every times of BLIPC procedure ended, and assayed with the immuno-turbidimetry assay on the coagulation laboratory autoanalyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Who Got New Brain Lesions</measure>
    <time_frame>300 days after treatment</time_frame>
    <description>We compared the number of patients who got new lesions in the Diffusion-weighted magnetic resonance imaging (DWI-MRI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Time Point Until the First Stroke Recurrence,</measure>
    <time_frame>At the 300-day after the initial treatment</time_frame>
    <description>These patients underwent MRI/DWI at the time of first recurrence; patients without symptoms recurrence underwent follow-up MRI/DWI at 300 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Perfusion Improvement Are Evaluated With SPECT and TCD</measure>
    <time_frame>300-day after treatment</time_frame>
    <description>Brain perfusion status were evalvated by SPECT SPECT scanning was performed using a dual headed rotating gamma camera at 30 minutes after intravenous 99mTc-ECD (25mCi) bolus injection and at 40 minutes after 18F -FDG bolus injection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">196</enrollment>
  <condition>Cerebrovascular Disease</condition>
  <arm_group>
    <arm_group_label>RIPC+stroke secondary prevension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure/Surgery: Remote Ischemic Preconditioning (RIPC) The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stroke secondary prevention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Remote ischemic preconditioning (RIPC)</intervention_name>
    <description>The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.</description>
    <arm_group_label>RIPC+stroke secondary prevension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients with stroke or transient ischemic attack (TIA) within 180 days and the
             neurologic deficits were well matched to the territory of the stenosed artery, with
             intracranial arterial stenosis of at least 50% by angiography, at least 70% by
             ultrasound, or at least 70% by computed tomographic angiography (CTA) or magnetic
             resonance angiography (MRA)

          2. Age between 18 to 80 years old

          3. Trial of Org 10172 in Acute Stroke Treatment-1 (TOAST-1) subtype

          4. National Institutes of Health Stroke Scale (NIHSS) score 0-15, and Modified Rankin
             Scale (mRS) score 0-4.

          5. ABCD2 score between 6 to 7

          6. Stable vital signs, normal hepatic and renal functions,

          7. No hemorrhagic tendencies.

        Exclusion criteria:

          1. Within 72 hrs of intra-artery or intravenous thrombolysis

          2. Intracranial hemorrhage or large area of cerebral infarction (more than 1/3 middle
             cerebral artery perfusion territory)

          3. Any soft tissue, orthopedic, or vascular injury, wounds or fractures in extremities
             which may pose a contraindication for application of the preconditioning cuffs

          4. Acute myocardial infarction

          5. Systolic blood pressure more than 200 mmHg after drug control

          6. Peripheral blood vessel disease

          7. Hematologic disease

          8. Severe hepatic and renal dysfunction

          9. Severe or unstable concomitant disease

         10. Cannot tolerate BLIPC or without informed consent

         11. Patients who did not complete the whole treatment procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xuanwu Hospital, Capital Medical University</name>
      <address>
        <city>Xicheng District</city>
        <state>Beijing P.R.</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2011</study_first_posted>
  <results_first_submitted>January 11, 2012</results_first_submitted>
  <results_first_submitted_qc>March 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2012</results_first_posted>
  <last_update_submitted>March 30, 2012</last_update_submitted>
  <last_update_submitted_qc>March 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Ji Xunming</investigator_full_name>
    <investigator_title>Xuan Wu Hospital</investigator_title>
  </responsible_party>
  <keyword>ischemic cerebral vascular disease</keyword>
  <keyword>stroke secondary prevention</keyword>
  <keyword>remote ischemic preconditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroprotective Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RIPC+Stroke Secondary Prevension</title>
          <description>Procedure/Surgery: RIPC The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
Procedure:stroke secondary prevention</description>
        </group>
        <group group_id="P2">
          <title>Stroke Secondary Prevention</title>
          <description>Procedure:stroke secondary prevention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RIPC+Stroke Secondary Prevension</title>
          <description>Procedure/Surgery: RIPC The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
Procedure:stroke secondary prevention</description>
        </group>
        <group group_id="B2">
          <title>Stroke Secondary Prevention</title>
          <description>Procedure:stroke secondary prevention</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="10.1"/>
                    <measurement group_id="B2" value="60" spread="9.4"/>
                    <measurement group_id="B3" value="60.5" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Blood Pressure and Heart Rates;</title>
        <time_frame>at the time points of baseline and 1, 15 and 30 days after BLIPC treatment</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Biomarkers of Coagulation and Fibrinolysis</title>
        <description>blood samples were collected one hour after every times of BLIPC procedure ended, and assayed with the immuno-turbidimetry assay on the coagulation laboratory autoanalyzer</description>
        <time_frame>the time points of baseline and 1, 15 and 30 days after BLIPC treatment</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Got New Brain Lesions</title>
        <description>We compared the number of patients who got new lesions in the Diffusion-weighted magnetic resonance imaging (DWI-MRI)</description>
        <time_frame>300 days after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RIPC+Stroke Secondary Prevension</title>
            <description>Procedure/Surgery: RIPC The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
Procedure:stroke secondary prevention</description>
          </group>
          <group group_id="O2">
            <title>Stroke Secondary Prevention</title>
            <description>Procedure:stroke secondary prevention</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Got New Brain Lesions</title>
          <description>We compared the number of patients who got new lesions in the Diffusion-weighted magnetic resonance imaging (DWI-MRI)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time Point Until the First Stroke Recurrence,</title>
        <description>These patients underwent MRI/DWI at the time of first recurrence; patients without symptoms recurrence underwent follow-up MRI/DWI at 300 days.</description>
        <time_frame>At the 300-day after the initial treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain Perfusion Improvement Are Evaluated With SPECT and TCD</title>
        <description>Brain perfusion status were evalvated by SPECT SPECT scanning was performed using a dual headed rotating gamma camera at 30 minutes after intravenous 99mTc-ECD (25mCi) bolus injection and at 40 minutes after 18F -FDG bolus injection.</description>
        <time_frame>300-day after treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RIPC+Stroke Secondary Prevension</title>
          <description>Procedure/Surgery: RIPC The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
Procedure:stroke secondary prevention</description>
        </group>
        <group group_id="E2">
          <title>Stroke Secondary Prevention</title>
          <description>Procedure:stroke secondary prevention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.6</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>transient sporadic subcutaneous bleeding points</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Xunming Ji, M.D.,Ph.D.</name_or_title>
      <organization>XuanWu Hospital, Capital Medical University</organization>
      <phone>8683198127</phone>
      <email>jixm70@hotmail.com , Jixm@ccmu.edu.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

